SN

Suraj Neminath Magdum

Active Director Additional Director DIN 10364350
DIN 10364350 First appointment Nov 2023 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Nov 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Suraj Neminath Magdum

Data last updated:

Suraj Neminath Magdum is an Additional Director at Royter Pharma Private Limited (since 2023). The company operates in Chemicals.

DIN 10364350
Primary Designation Additional Director
Industry Chemicals
First Appointment 06 Nov 2023
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Royter Pharma Private Limited U24290PN2022PTC214579
Additional Director06 Nov 20232022Active

Board colleagues of Suraj Neminath Magdum

Directorship timeline

Open interactive timeline →
Royter Pharma Private Limited
Premium access

Shareholding and investment profile for Suraj Neminath Magdum

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Suraj Neminath Magdum

Suraj Neminath Magdum currently holds 1 directorship: Royter Pharma Private Limited (Additional Director, since 06 Nov 2023).

Suraj Neminath Magdum was first appointed on 06 Nov 2023 as Additional Director at Royter Pharma Private Limited.

The current boards of Suraj Neminath Magdum's companies include Bharat Kumar Mankapure (Royter Pharma Private Limited), Jain Vishal Dhanyakumar (Royter Pharma Private Limited), Siddharth Appaso Shedshale (Royter Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available